Opioids
3 Results
- Thematic review on gastroenterological diseases
Chronic Constipation
Mayo Clinic ProceedingsVol. 94Issue 11p2340–2357Published online: May 1, 2019- Adil E. Bharucha
- Arnold Wald
Cited in Scopus: 76Constipation is a common symptom that may be primary (idiopathic or functional) or associated with a number of disorders or medications. Although most constipation is self-managed by patients, 22% seek health care, mostly to primary care physicians (>50%) and gastroenterologists (14%), resulting in large expenditures for diagnostic testing and treatments. There is strong evidence that stimulant and osmotic laxatives, intestinal secretagogues, and peripherally restricted μ-opiate antagonists are effective and safe; the lattermost drugs are a major advance for managing opioid-induced constipation. - Symposium on pain medicine
Common Functional Gastroenterological Disorders Associated With Abdominal Pain
Mayo Clinic ProceedingsVol. 91Issue 8p1118–1132Published in issue: August, 2016- Adil E. Bharucha
- Subhankar Chakraborty
- Christopher D. Sletten
Cited in Scopus: 37Although abdominal pain is a symptom of several structural gastrointestinal disorders (eg, peptic ulcer disease), this comprehensive review will focus on the 4 most common nonstructural, or functional, disorders associated with abdominal pain: functional dyspepsia, constipation-predominant and diarrhea-predominant irritable bowel syndrome, and functional abdominal pain syndrome. Together, these conditions affect approximately 1 in 4 people in the United States. They are associated with comorbid conditions (eg, fibromyalgia and depression), impaired quality of life, and increased health care utilization. - Symposium on pain medicine
Alternative Splicing of G Protein–Coupled Receptors: Relevance to Pain Management
Mayo Clinic ProceedingsVol. 90Issue 8p1135–1151Published in issue: August, 2015- Folabomi A. Oladosu
- William Maixner
- Andrea G. Nackley
Cited in Scopus: 22Drugs that target G protein–coupled receptors (GPCRs) represent the primary treatment strategy for patients with acute and chronic pain; however, there is substantial individual variability in both the efficacy and adverse effects associated with these drugs. Variability in drug responses is due, in part, to individuals’ diversity in alternative splicing of pain-relevant GPCRs. G protein–coupled receptor alternative splice variants often exhibit distinct tissue distribution patterns, drug-binding properties, and signaling characteristics that may impact disease pathology as well as the extent and direction of analgesic effects.